Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign announces agreement for distribution of OSSDSIGN Cranial in the USA with Mat

STOCKHOLM - February 2, 2017 Karolinska Development AB (Nasdaq Stockholm:
KDEV) notes that portfolio company OssDsign AB
, a Swedish designer, manufacturer and distributor of next generation implants
for cranial and facial reconstruction, has today announced it has signed an
agreement with Matador Medical Inc. to act as its master distributor in the
US market. OssDsign recently announced FDA 510(k) clearance of OSSDSIGN
Cranial PSI, a patient-specific medical implant intended for reconstruction
of cranial defects.

Details from the OssDsign announcement follow:

Matador Medical was founded and is led by Paul Byerley, who was previously
senior vice president at Apatech Inc, the US subsidiary of a British company
that after a successful US sales expansion was acquired by Baxter Inc in
2010. OssDsign's chairman, Simon Cartmell, is the former CEO of Apatech Ltd.
Matador Medical is based in Temecula, CA.

Matador Medical, as master distributor, will recruit and manage a network of
sales and distribution professionals that will allow OssDsign to reach all
relevant surgical centres and key opinion leaders throughout the US. The
Company's sales and marketing operations are scheduled to start on March 1,

Anders Lundqvist, CEO of OssDsign, said: "We are delighted to sign this new
commercial agreement with Matador Medical. Working with Matador Medical gives
us a unique opportunity to access experienced sales and distribution
professionals with established relations with our key US customers, allowing
us to quickly get our products in front of relevant clinicians and

Paul Byerley, General Manager of Matador Medical, said: "Getting to know the
OssDsign team and understanding the technology behind OSSDSIGN Cranial has
made me realize that this is a very special product with great potential in
the US market. Initial reactions from US surgeons have been positive and we
are certainly excited to be able to bring OSSDSIGN Cranial to the market
where we believe it will have an important impact."

Viktor Drvota, Chief Investment Officer at Karolinska Development, said:
"OssDsign has got off to a flying start in 2017 and is making great progress
in building a broad commercial network covering the major markets of the US
and Europe for its innovative medical implants. In Matador Medical, OssDsign
has a highly experience and well-connected partner with a successful
commercial track record in the US, which will be crucial to support a strong
launch of OSSDSIGN Cranial following its 510(k) clearance in January. "

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail:

Christian Tange, CFO, Karolinska Development AB

Phone: +46 73 712 14 30, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson

Phone: +44 20 7638 9571; e-mail:


About OssDsign AB

OssDsign is a Swedish medtech company dedicated to creating regenerative
implants for improved healing of bone defects and deficits in skull, facial
and other types of surgery. OssDsign has successfully launched its first
patient specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany,
the UK and the Nordic countries, and further global market expansion is

By combining clinical insight with proprietary material technology and patient
adapted design, OssDsign supplies an expanding range of tailored solutions
for cranial repair and facial bone reconstruction. OssDsign's technology is
the result of collaboration between clinical researchers at the Karolinska
University Hospital, Stockholm, and material science experts at the Ångström
Laboratory at Uppsala University. Main investors in OssDsign are Karolinska
Development, SEB Venture Capital, Fouriertransform and Almi Invest. For more

About OSSDSIGN® Cranial

OSSDSIGN Cranial PSI is a patient specific implant intended for the
reconstruction of cranial defects. It is indicated for non-load bearing
applications for patients in whom cranial growth is complete. The implant is
made from a proprietary calcium phosphate formulation which is reinforced by
a 3D printed titanium skeleton.

About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying
medical innovation and investing in the creation and growth of companies
developing these assets into differentiated products that will make a
difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of 10 companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by a team including investment professionals with strong
venture capital backgrounds, experienced company builders and entrepreneurs,
with access to a strong global network. For more information, please visit

OssDsign Matador

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.